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Abstract 1 
Transcriptional dysregulation induced by aberrant Transcription factors (TFs) is a key feature 2 
of cancer, but its global influence on drug sensitivity has not been examined. Here we infer 3 
the transcriptional activity of 127 TFs through analysis of RNA-seq gene expression data 4 
newly generated for 448 cancer cell lines, combined with publicly available datasets to 5 
survey a total of 1,056 cancer cell lines and 9,250 primary tumors. Predicted TF activities are 6 
supported by their agreement with independent shRNA essentiality profiles and homozygous 7 
gene deletions, and recapitulate mutant-specific mechanisms of transcriptional dysregulation 8 
in cancer. By analysing cell line responses to 265 compounds, we uncovered numerous TFs 9 
whose activity interacts with anti-cancer drugs. Importantly, combining existing 10 
pharmacogenomic markers with TF activities often improves the stratification of cell lines in 11 
response to drug treatment. Our results, which can be queried freely at 12 
dorothea.opentargets.io, offer a broad foundation for discovering opportunities to refine 13 
personalised cancer therapies. 14 
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Introduction 1 
Transcriptional dysregulation is required for tumor progression and drug resistance 2 
acquisition. Many cancer driver genes are transcription factors (TFs). Notable examples 3 
include TP53, the most commonly mutated tumor suppressor that controls cell growth 4 
arrest(1), and HIF1A, a key regulator of the adaptive response to hypoxia and 5 
angiogenesis(2). TFs are commonly dysregulated due to genomic alterations or aberrations 6 
in their regulatory proteins. For example, TP53 activity can be suppressed through 7 
amplification of its repressor MDM2(3) and HIF1A upregulation is often induced by loss-of-8 
function mutations in VHL(4). Due to their role as downstream signalling effectors, aberrant 9 
activities of any pathway protein may dysregulate TF activities, altering the expression of its 10 
transcriptional targets or “regulon”. Different from driver alterations in kinase-mediated 11 
signalling cascades, where redundancy provides compensatory mechanisms, aberrant 12 
transcriptional regulators have been argued to be harder to circumvent by secondary 13 
genomic alterations(5). Consequently, TFs have been proposed as key nodal oncogenic 14 
drivers and their activity patterns used to characterise genomic aberrations in cancer(6,7) or 15 
their influence on a patient's prognosis(8). 16 
Recently, the Genomics of Drug Sensitivity in Cancer (GDSC)(9,10), Cancer Therapeutics 17 
Response Portal (CTRP)(11) and Cancer Cell Line Encyclopedia (CCLE)(12) have 18 
generated large-scale public pharmacogenomic datasets spanning multiple molecular data 19 
types across hundreds of cancer cell lines. These datasets enabled the identification of 20 
genomic, transcriptomic and epigenomic markers of drug sensitivity(9,10,12) and have 21 
uncovered a complex network of genomic alterations interacting with sensitivity to hundreds 22 
of drugs. The challenge is now to dissect the underlying molecular mechanisms regulating 23 
drug response, for which novel and more systemic functional approaches are needed.  24 
Here we used TF regulatory activities as sensors of pathway dysregulation. Assuming that 25 
the activity of a TF can be estimated from the mRNA levels of its direct target genes, defined 26 
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from prior TF-gene regulatory data, we derived single-sample TF activity profiles across 1 
9,250 primary tumors from the Cancer Genome Atlas (TCGA) and 1,056 cancer cell lines, 2 
employing newly generated RNA-seq data for 448 cancer models. We evaluated the 3 
prediction accuracy on independent genomics and gene-essentiality screens. Then, we 4 
mined for statistical interactions between somatic mutations and TF activities. To 5 
discriminate mutant-specific effects, we functionally re-annotated somatic mutations based 6 
on the affected protein feature (e.g. regulatory sites, protein interactions, truncation, etc.). 7 
Finally, we investigated TF activities alone or in combination with genomic markers as 8 
potential predictors of sensitivity to 265 compounds, performing a large-scale evaluation of 9 
TFs as markers of drug sensitivity in cancer. The collection of identified interactions is 10 
publicly available at http://dorothea.opentargets.io.  11 
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Materials and Methods 1 
Cell lines and primary tumors data 2 
RNA from 448 cell lines was sequenced in-house (Table S1A). Cell lines were sourced from 3 
collaborators or repositories and have been used for GDSC(9,10) and COSMIC cell line(13) 4 
projects. These have been cryopreserved in aliquots in liquid nitrogen for 7 years in the lab. 5 
A single cryovial were thawed for use and propagated for a maximum of 3 months before 6 
being discarded. All cell lines were mycoplasma negative. Cell line’s identity was compared, 7 
where possible, against those provided by the repositories (ATCC, Riken, JCRB and DSMZ) 8 
using a panel of 16 STRs (AmpFLSTR Identifiler KIT, ABI) and the corresponding genotype 9 
data is available at COSMIC database (http://cancer.sanger.ac.uk/cell_lines). RNA libraries 10 
were made with the Stranded mRNA library kit from KAPA Biosystems according to the 11 
manual using the Agilent Bravo platform. Libraries were sequenced on an Illumina HiSeq 12 
2000. Raw and processed data were deposited on the European Genome-phenome Archive 13 
(EGAS00001000828) and ExpressionAtlas (E-MTAB-3983). For the other cell lines, RNA-14 
seq fastq files were downloaded from CCLE(12) (PRJNA169425) and Klijn et 15 
al(14)(EGAS00001000610). To minimise technical biases, the 3 datasets were re-analysed 16 
using iRAP(15) to obtain raw counts. TCGA samples’ raw counts were downloaded from the 17 
Gene Expression Omnibus (GSE62944)(16). Raw counts were normalised and processed 18 
into counts per million reads (Supplementary Methods).  19 
For cell lines, Whole Exome Sequencing (WES), Copy Number Alterations (CNA), 20 
methylation and drug response data were retrieved from the GDSC1000 web-portal(10), 21 
while gene essentiality scores were downloaded from the Project-Achilles web-portal(17). 22 
For primary tumors, WES, CNA and clinical data were retrieved from cBioportal 23 
(Supplementary Methods). Tables S1A-D list all samples and data types. 24 
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Consensus TF regulons data 1 
We defined a set of high-confidence human TFs from the table S3 provided in Vaquerizas et 2 
al(18), by excluding unlikely TFs noted as “x”. Secondly, we retrieved TF-target regulatory 3 
interactions from public resources covering different TF-binding evidences, including TF 4 
binding site (TFBS) predictions, chromatin immunoprecipitation coupled with high-throughput 5 
data (ChIP-X), text-mining derived and manually curated TF-target interactions 6 
(Supplementary Methods). For each TF, we defined a consensus TF regulon (CTFR) 7 
selecting TF-target interactions reported in more than one source (Table S2). TF-target 8 
interactions are unsigned and unweighted.  9 
Scoring basal TF activities 10 
Given a matrix of normalised gene expression values per sample, the first step consisted in 11 
a gene-wise normalisation employing a kernel estimator of the cumulative density function 12 
(kcdf)(19). Next, the level of activity of a TF regulon in a sample was approximated as a 13 
function of the collective mRNA levels of its targets using aREA (analytic Rank-based 14 
Enrichment Analysis), a statistical method from the VIPER R package based on the mean 15 
ranks’ comparisons(6). aREA’s normalised enrichment scores (NES) were used as 16 
estimates of regulon relative activity. Positive and negative scores indicated, respectively, 17 
greater or weaker relative activity in a sample compared to the background population (cell 18 
lines or TCGA samples). The aREA algorithm was selected because it takes into account 19 
the effect (activation/repression) of the TF on each target, thus enabling comparisons with 20 
other types of regulatory networks. R code to compute TF activities is available at 21 
https://github.com/saezlab/DoRothEA 22 
Comparison between normal and primary tumors 23 
Differential TF activities contrasting normal and tumoral TCGA samples were computed 24 
using the limma R package. The matrix of relative activities per sample was used to fit a 25 
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linear model for each TF (lmFit) and the eBayes test used to obtain the corresponding 1 
moderated t-statistics, nominal and adjusted p-values.  2 
Association analysis with TF and driver mutations 3 
We grouped somatic variants in driver genes according to their potential implications at the 4 
protein-level (Supplementary Methods). Next, we analysed the association between each 5 
group of mutations and the activity of a TF with an analysis-of-variance (ANOVA) test as in 6 
(10). To ensure comparable measurements among datasets and groups of mutations, we 7 
removed confounding effects by regressing-out effects associated with tissue lineage from 8 
the TF activity profiles. Next, for each mutation group/TF pair, the corrected TF activities 9 
were modeled as a function of the mutation status. The change in TF activity between 10 
mutants and wild-type samples was defined by Cohen’s d effect size and significance were 11 
estimated with type-II ANOVA using the car R package. P-values were adjusted for multiple 12 
testing corrections (Benjamini-Hochberg method) on a gene basis. 13 
Association analysis with drug response  14 
We used a linear model to correlate drug responses with TF activities. For each drug-TF 15 
pair, drug IC50s across all samples (YIC50) were modeled as a function of the dependent 16 
covariates (Xcovariates, including tissue-type in pan-cancer analyses, microsatellite instability 17 
status and screening medium), TF estimated activity (XTF) and noise (𝜓):  18 
𝑌𝐼𝐶50 =  𝛽𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠𝑋𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠  +  𝛽𝑇𝐹𝑋𝑇𝐹  +  𝜓 19 
The impact of the TF on drug response was defined by the regression coefficient (𝛽TF ) 20 
estimated with a multiple linear least squares regression. Significance of the regressors was 21 
estimated with a type-II ANOVA using the car R package. Finally, for each cancer-type, p-22 
values were adjusted for multiple testing corrections using the Benjamini-Hochberg method.  23 
In the pan-cancer analysis, the tissue-type was defined by the GDSC_description2 due to 24 
the presence of several cell lines without a matching TCGA label. In cancer-specific 25 
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analyses, we grouped the samples according to the TCGA labels, for consistency with the 1 
GDSC1000 study(10). We additionally tested Ewing's sarcoma, leukemia, lymphoma, 2 
osteosarcoma and rhabdomyosarcoma tumor-types. 3 
Association analysis between TF activities and known pharmacogenomic markers 4 
Large-effect significant pharmacogenomic markers (p<0.001, FDR<20% and Glass∆s>1) 5 
were extracted from GDSC1000(10). For each pharmacogenomic marker (GM), we fit a null 6 
multiple regression model (Mnull) where the independent variable is the drug IC50 (YIC50) and 7 
the dependent variables are the cell line covariates (tumor type, MSI, and screening media; 8 
Xcovariates), the genomic marker (XGM) and a noise term (𝜓 ): 9 
𝑀𝑛𝑢𝑙𝑙: 𝑌𝐼𝐶50  =  𝛽𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠𝑋𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠  +  𝛽𝐺𝑀𝑋𝐺𝑀 +  𝜓 10 
Next, for each TF in our panel, we built a nested regression model (MTF) containing the same 11 
variables of Mnull plus the activities of the TF (XTF) and their interaction with GM (XGM*TF) : 12 
𝑀𝑇𝐹: 𝑌𝐼𝐶50  =  𝛽𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠𝑋𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠  +  𝛽𝐺𝑀𝑋𝐺𝑀 +  𝛽𝑇𝐹𝑋𝑇𝐹  + 𝛽𝐺𝑀∗𝑇𝐹𝑋𝐺𝑀∗𝑇𝐹 +  𝜓 13 
Every MTF was compared to the corresponding null model Mnull using a Likelihood Ratio (LR) 14 
test. Resulting p-values were adjusted using the Benjamini-Hochberg method.   15 
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Results 1 
TF activities estimation  2 
First, we assembled a collection of basal transcriptional profiles of immortalised human 3 
cancer cell lines and primary tumors (Figure 1A). For cancer cell lines, we newly derived 4 
RNA-seq data from 448 samples, that we complemented with RNA-seq profiles from 934 5 
and 622 cell lines, respectively from the CCLE(12) and Klijn et al(14). This yielded a total of 6 
1,362 unique cancer cell lines, of which 1,056 are in COSMIC(13) (Table S1A). To minimise 7 
technical biases, we derived raw counts using a common pipeline. For primary tumors, we 8 
downloaded RNA-seq raw counts for 9,250 TCGA primary tumors and 741 normal 9 
samples(16). Cell lines and TCGA samples were processed and normalised separately. 10 
 11 
To define the TF regulons (i.e. sets of genes whose transcription is regulated by a given TF), 12 
we collected 15,211 TF-targets interactions appearing in at least 2 publicly available 13 
resources (hereafter Consensus TF Regulons, CTFR; Figures 1B and S1A-B; Table S2). To 14 
ensure a minimum signal when we compute the TF activities, we removed targets regulated 15 
by more than 10 TFs and TFs with less than 3 targets in the expression matrix. The final 16 
CTFRs consisted of 7,445 targets for 127 TFs, with 111 targets per TF on average (Figure 17 
S1C). Pairwise overlap between regulons was low (average Jaccard Similarity 18 
Coefficient=0.0044, Figure S1D), indicating negligible levels of redundancy between CTFRs.  19 
 20 
Next, we normalised the transcriptomic data gene-wisely to estimate relative levels of basal 21 
activity of each CTFR in each sample using the aREA algorithm(6). Cell lines and TCGA 22 
samples (tumor+normal) were analysed separately (Figure 1C; Tables S3A-B). Normalised 23 
enrichment scores (NES) (Figure S2A-D) were used as estimates of CTFR activity relative to 24 
the background population (hereafter simplified as ‘TF activities’). Subsampling analysis 25 
revealed that activity estimates were robust in populations with n≥20 (Figure S2E).  26 
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 1 
We evaluated the TF activity estimations using independent benchmark data derived from 2 
an essentiality screening(17), and CNA and WES data in cell lines (Supplementary 3 
Methods). Moreover, we investigated the inclusion of methylation data as a means to refine 4 
CTFRs on a cell line-basis excluding from the regulons those targets with hypermethylated 5 
promoters, not observing significant performance improvements (Supplementary File, 6 
Figures S3-S4). Finally, we compared the activities derived from the CTFRs against those 7 
derived from reverse-engineered regulons proposed in (6), observing slightly better 8 
performances for CTFRs (Supplementary File, Figures S3-S6). Hence, we selected CTFRs-9 
based estimations (without including promoter methylation information) for our downstream 10 
analysis. 11 
TF activities across primary tumors and cell lines 12 
To obtain a global picture of TFs operating in primary tumors, we studied how TF activities 13 
distribute across TCGA samples. Differential activity analysis of normal versus tumor 14 
samples revealed groups of TFs consistently activated or repressed across the 14 tumor 15 
types with matched normal samples. While most TF regulons decrease their activity, a small 16 
subset undergoes a recurrent increase across tumor types (Figure 2A), including oncogenic 17 
regulators of cell cycle (MYC, MAX, E2F family members, FOS and FOXM1), tumor invasion 18 
and angiogenesis (ELK1 and ETS1)(20).  19 
 20 
Next, we compared the TF profiles between cancer types. First, we summarised sample-21 
level activities into cancer-level activities. For each TF, we ranked the samples based on TF 22 
activity and quantified the enrichment of each cancer-type at the top of the ranks using the 23 
aREA algorithm (Figure S7A-B, Table S3C-D). Hierarchical clustering based on euclidean 24 
distance highlighted similar activity profiles for primary tumors from the same tissue lineage 25 
such as the diffuse gliomas GBM and LGG, hematopoietic and lymphoid LAML and DLBC or 26 
squamous-like tumors BLCA, CESC, HNSC and LUSC (Figure 2B). These clusters were 27 
Research. 
on December 18, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 11, 2017; DOI: 10.1158/0008-5472.CAN-17-1679 
11 
also observed in the cell lines (Figure S7C). Correlation analysis revealed a significant 1 
agreement in the TF profiles between cell lines and primary tumors from the same tissue 2 
lineage (average Pearson correlation 0.5 and -0.035 within and between different tumor 3 
types respectively, Figure 2C).  4 
 5 
Closer examination of well-established tissue-specific TFs (retrieved from the Human 6 
Cancer Protein Atlas v15(21)) showed that our approach captures 11 out of 12 TFs 7 
operating preferentially in specific tissues in primary tumors (Figure 2D) such ESR1 and 8 
FOXA1 in BRCA or MITF in SKCM. Note that for ZEB1, a transcriptional repressor involved 9 
in epithelial-to-mesenchymal transition (EMT)(22), higher protein activities correspond to a 10 
downregulation of the regulon. Importantly, these tendencies are maintained in the cell lines 11 
with the exception of AR, where 4 out of 6 prostate cell lines display AR-independent 12 
proliferation (Table S1C). Taken together, these results show that our approach captures 13 
expected activity patterns of known cancer-specific TFs.  14 
TF activities dissect mutant-specific aberrations 15 
Previous studies demonstrated that different mutations in the same protein could cause a 16 
continuum of effects, ranging from neutrality to a significant functional impact(23). We thus 17 
set-out to characterise the effect of mutations occurring in TFs on their own activity. As proof 18 
of concept, we focused on TP53 due to its high mutation frequency and heterogeneity. We 19 
curated TP53 mutations according to specific mutations, hotspots, protein consequence, 20 
zygosity (in cell lines), affected domain, PTM or structural property and previously proposed 21 
mutation stratifiers(24) (Table S4A). Subsequently, we compared predicted TP53 activities of 22 
each TP53 mutation group with wild-type samples (Figure 3A). To avoid confounding effects 23 
due to the use of different samples and tumor types, we regressed-out the tissue lineage 24 
from the TF activity profiles through linear modelling. Our results indicated that all TP53 25 
mutation groups significantly affecting TP53 transcriptional activity decreased it (Figure S8; 26 
Table S4B). Overall, homozygous mutations and deletions had a stronger effect size than 27 
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heterozygous mutations (Figure 3B). Focusing on the most frequent mutational hotspots 1 
revealed that R231X and R273C reached larger effect sizes than R248Q and R175H 2 
substitutions in both primary tumors and cell lines. However, direct pairwise comparison 3 
between mutants did not yield significant results alone. Importantly, these significant 4 
changes in activity were correlated between primary tumors and cell lines (R2=0.551, 5 
p=1.14×10-8, Figure 3C). This suggests that transcriptional activity prediction may better 6 
capture effect on TP53 activity than mutation alone. This is supported by comparison of 7 
activity predictions with experimentally defined TP53 mutant yeast transactivation class from 8 
the IARC TP53 Database(25)where each possible TP53 missense mutation is assigned to a 9 
transactivation class -functional, partially or non-functional- according to its effects on the 10 
transcription of 8 TP53-responsive promoters in yeast). Comparison between non-functional 11 
and the other missense mutants showed a significant agreement with our predictions in cell 12 
lines (one-tailed t-tests, p=0.00535) and, although marginally significant, in primary tumors 13 
(p=0.0418).  14 
 15 
Motivated by these results, we investigated systematically the effect of mutations in TFs on 16 
their activity. To distinguish mutant-specific effects, these were studied individually. 17 
Importantly, to consider non-recurrent yet potentially functional driver mutations, we also 18 
grouped mutations that, although introducing different changes in different residues, could 19 
affect protein function in a similar way (e.g. same structural region, interaction or post-20 
translational modification site). We recovered 1,200 mutation groups in 122 TFs from 21 
primary tumors (n≥3). Pancancer analysis in primary tumors identified 9 TFs that, when 22 
mutated, exhibit a significant change in activity(FDR<5%; Figure 3D, Table S4C). In general, 23 
mutations in TFs with known oncogenic roles, such as NFE2L2, HIF1A and AHR were 24 
associated with increased regulatory activity, pointing to gain-of-function mutations. In 25 
contrast, mutations in the proposed tumor suppressors STAT2 and FOXA1 are associated 26 
with decreased activity. Also, truncating mutations in the transcriptional repressor REST 27 
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resulted in increased regulon expression (Figure 3E). Analysing cell lines showed similar 1 
trends for REST truncating mutations (p=0.00367, FDR=0.0367) and NFE2L2 missense 2 
mutation in D29 (p=0.009, FDR=0.099). 3 
 4 
Closer examination of results revealed again differences in the effect of mutation types on 5 
protein activity. In NFE2L2, a cytoprotective oncogene, missense mutations affecting 6 
p.W24/p.D29 residues at the surface or at the KEAP1-interface (positions 77-82) are 7 
associated with higher NFE2L2 activity, with NFE2L2W24R/C mutations causing the strongest 8 
increase(Figure 3E). Mutations at the KEAP1-binding site were already proposed to be 9 
positively selected to abolish NFE2L2 degradation(26).  10 
Associations with known driver mutations  11 
Next, we evaluated how mutations in any cancer driver genes, proposed in(27,28), could 12 
impact TF activities. We grouped mutations in driver genes following the same strategy 13 
described for TFs. This yielded 1,774 mutation groups (n ≥ 5) in 171 driver genes. 14 
Systematic comparisons of TF activities in mutant against wild-type primary tumors yielded 15 
3,565 driver mutation groups-TF associations involving 97 driver genes and 75 TFs 16 
(FDR<5%, Figure 4A-B; Table S5A). The same analysis in cell lines allowed us to study only 17 
533 mutation groups, and rendered fewer associations (probably due to lower sample 18 
number) that involved 36 interactions between 17 drivers and 25 TFs (FDR<5%, Table S5B). 19 
Importantly, 12 hits were shared between primary tumors and cell lines with concordant 20 
effect (Fisher’s exact test (FET), odds-ratio=7.89 p<1.32×10-6, Figure 4C). Some of these 21 
associations represent proposed mechanisms of TF regulation, such as the repression of 22 
E2F1 by RB1, perhaps the best-described inhibitor of TF function(29), or ELK1 regulation by 23 
ERK-MAPK pathway(20,30).  24 
 25 
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To assess whether the detected associations represent plausible driver-TF regulatory 1 
events, we extracted directed edges from literature-curated signalling networks from 2 
OmniPath(31) and quantified shortest path lengths between every driver-gene/TF pair. 3 
Enrichment analysis confirmed that significant driver-gene/TF associations tend to be closer 4 
than non-significant associations (Figure 4D). Next, we investigated whether the predicted 5 
effect of driver mutations on TF activities (association sign) agrees with the TF’s role in 6 
cancer. We classified TFs into 3 groups according to their role in cancer: (i) up-regulated in 7 
cancer, if the TF displays significant greater activity in tumor than in normal samples or is a 8 
known oncogene(27,28); (ii) down-regulated, if the TF function is repressed in tumor 9 
samples or is a tumor suppressor; or (iii) neutral. Enrichment analysis revealed that positive 10 
driver/TF interactions (i.e. potential TF-activating events) tend to involve cancer upregulated 11 
TFs, in contrast, negative interactions are more prone to involve cancer downregulated TFs 12 
(Figure 4E). Taken together, our results suggest that the identified associations point to 13 
potential mechanisms of driver-mediated transcriptional dysregulation in cancer.  14 
Drug sensitivity interactions in 984 cancer cell lines 15 
We next investigated the potential of TF activities as markers of response to 265 compounds 16 
across 984 cancer cell lines(10). Association between TF-drug pairs was tested with a linear 17 
regression approach accounting for potentially confounding factors (tissue lineage, 18 
microsatellite instability and cell lines growth media).  19 
 20 
A pancancer analysis identified 3,300 significant TF-drug associations (p<0.001, FDR<5%), 21 
with 251 drugs (95%) and 123 TFs (97%) implicated in at least one interaction (Table S6A). 22 
Most drugs were associated with multiple TFs, which, considering the relatively low overlap 23 
between regulons (Figure S1D) may correspond to functional cooperation in transcriptional 24 
regulators rather than target redundancy. In fact, interacting TFs display similar activity 25 
profiles (Figure S9). Most TF-drug associations involved relevant oncogenic TFs such as 26 
MYC, PAX5, MYCN, FOXA1 and GATA3 (Figure 5A; Table S6B-C). Significant associations 27 
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were enriched for cytotoxic drugs and compounds targeting cytoskeleton, metabolism, DNA 1 
replication, JNK-p38 and ERK-MAPK signalling (FET p<0.001, Figure 5B; Table S6D). 2 
 3 
Some of the investigated TFs are recurrently mutated in cancer and have already been 4 
proposed as genomic markers of drug sensitivity. To validate if TF activities are able to 5 
recapitulate the same drug-gene associations observed at the genomic-level, we compared 6 
our findings with the pharmacogenomic interactions (FDR<25% and p<0.001) previously 7 
identified for these cell lines(10). Our approach identified 12 out of the 21 significant 8 
pharmacogenomic interactions involving a TF in our panel (FET p=8.39×10-4, odds-9 
ratio=4.45), including TP53 mutations interacting with response to Nutlin-3a; MYC with 10 
Vismodegib and PAX5 with Bleomycin, among others. The same drug association analysis 11 
on TF activities derived from reverse-engineered regulons(6) instead of CTFRs (on the 12 
overlapping TFs) rendered fewer hits than CTFRs, none in the pharmacogenomic marker list 13 
(Figure S10).  14 
 15 
Next, we investigated whether TF activity predicts sensitivity to direct intervention of their 16 
upstream regulators with targeted drugs. We extracted from OmniPath the interactions 17 
involving the proteins targeted by the drugs. Enrichment analysis confirmed that significant 18 
hits were more likely to involve TFs directly connected to the targets of the associated drug 19 
(FET p=0.0155, odds-ratio=1.2), suggesting that predicted activities may be indeed 20 
indicative of upstream pathway activation and therefore useful sensitivity markers for drugs 21 
targeting their components. For example, sensitivity to drugs targeting the ERK-MAPK 22 
pathway (Figure 5C) was associated with increased activities in several MEK targeted TFs 23 
including SPI1, JUN, JUND and STAT3(32,33), whereas vulnerability to the two tested RSK-24 
inhibitors correlates with ELK1, another known downstream MAPK target(20,30).  25 
 26 
Also, our analyses also identified TFs showing simultaneous sensitivity interactions to drugs 27 
targeting common processes. For example, sensitivity to cytotoxic compounds was 28 
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associated with TFs classically upregulated in actively proliferating cells such as MYC, while 1 
activity of tissue-specific TFs (such as MITF, REST or HNF4A) was associated with 2 
resistance to these drugs (Figure 5D).  3 
 4 
The strongest detected association involved TP53 and Nutlin-3a (regression coefficient 5 
(coeff)=-0.57, p=x1.58×10-30, Figure 5E). Nutlin-3a is an MDM2-inhibitor that blocks MDM2-6 
mediated TP53 degradation. Our results agree with pharmacogenomic studies in that 7 
samples with lower TP53 activities show lower sensitivity to MDM2-inhibition(9,10). Another 8 
strong interaction was ZEB1 upregulation, an EMT marker, associated with resistance to 9 
EGFR inhibitor Afatinib (coeff=-0.53, p=5.19×10-15) and Gefitinib (coeff=-0.24, p=5.9×10-7). 10 
This is in agreement with a recent study in NSCLC describing ZEB1-mediated acquired 11 
resistance to EGFR-inhibitors(34).  12 
 13 
Cancer-specific analysis revealed fewer associations compared to the pancancer analysis, 14 
probably due to reduced sample size (Figure 5F; Table S6E). Still, we recovered 125 TF-15 
drug associations (p<0.001, FDR<10%), most in lymphoma, the largest subpopulation. 16 
Some hits involved drugs with no associated genomic markers (Figure 5G). Among the top 17 
hits we found that NFKB1 activity was associated with sensitivity to ITK inhibitor BMS-18 
509744 in Lymphoma cells (coeff=0.612, p=4.5×10-7); in STAD, sensitivity to PHA-793887, a 19 
pan-CDK inhibitor, was associated with YY1, recently proposed to contribute to gastric 20 
oncogenesis(35) (coeff=-1.05, p=5.9×10-7); in Myeloma, resistance to the tyrosine kinase 21 
inhibitor Sorafenib was associated with the activity of IRF1, a proposed tumor suppressor for 22 
Acute Myeloid Leukemia(36) (coeff=0.8, p=8.27×10-7); finally, sensitivity to the MEK inhibitor 23 
RDEA119 in HNSC associated with ZEB1 activity (coeff=-0.898, p=1.13×10-6) a key EMT 24 
effector in HNSC development(37). 25 
TF activities enhance the predictive ability of genomic markers  26 
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We showed before that the strongest TF-drug association detected involved the well-known 1 
interaction between TP53 and Nutlin-3a. According to previous studies, samples with TP53 2 
mutations are Nutlin3a-resistant(9,10), while our results suggest that samples with higher 3 
TP53 activities are more sensitive. We reasoned that protein activities might complement 4 
mutation-based markers to further improve the stratification of sensitive and nonsensitive cell 5 
lines. To test this hypothesis, we used a Likelihood Ratio test (LR) to compare 6 
pharmacogenomic models with and without including TF activities (Figure 6A). We confirmed 7 
that TP53 activity was able to further identify sensitive cell lines among wild--type samples 8 
(Figure 6B, p=2.1×10-15). None other TF outperformed TP53. This observation was 9 
reproduced in 3 out of 5 individual tumor types (OV, GBM and LAML; p<0.05) where TP53 10 
mutations are markers of Nutlin-3a response.  11 
 12 
Motivated by this finding we ran a systematic analysis to search for TFs able to refine known 13 
pharmacogenomic interactions. Overall, 95 out of 160 (59.4%) tested strong-effect 14 
pharmacogenomic interactions identified in(10) are improved by at least one TF (FDR<5%, 15 
LR test; Table S7). The second most significant hit after TP53-Nutlin3a involved the 16 
interaction between BRAF mutations and the FDA-approved BRAF inhibitor Dabrafenib. 17 
Specifically, in BRAF mutant samples, resistance to Dabrafenib interacts with ATF2 and 18 
MITF activity (Figure 6C, p=1.2×10-12 and p=4.68×10-10). Resistance in BRAF mutants to 19 
Dabrafenib was still observable in SKCM samples with higher ATF2-targets expression 20 
(p=0.00123). The importance of ATF2 in melanoma is supported by several lines of 21 
evidence; ATF2 is required for melanoma tumor development(38) nuclear ATF2 22 
(transcriptionally active) is associated with poor prognosis and genotoxic stress-23 
resistance(39). Moreover, PKCε, the kinase mediating ATF2 transcriptional activity, is 24 
among the top 10 kinases associated with BRAF-inhibition resistance, which supports the 25 
relationship between ATF2 and Dabrafenib resistance(40). In fact, ATF2 essentiality scores 26 
from Achilles project(41) correlate with the predicted activity for ATF2 in BRAFV600E mutant 27 
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samples at the pancancer-level (Pearson correlation, R=-0.615, p=0.0332; Figure S11A) but 1 
not in BRAFwt (R=0.082, p=0.347; Figure S11B). 2 
 3 
Interestingly, the most significant improvements in predictions were observed between drugs 4 
targeting ERK-MAPK signalling (FET p=5.28×10-6) and the driver genes BRAF, KRAS or 5 
HRAS. For example, in BRAF wild-type samples, sensitivity to MEK inhibitors improved 6 
including JUND in the model, among others (p=1.86×10-11, p=3.12×10-11 and p=1.77×10-8; 7 
Trametinib, RDEA119 and AZD6244, respectively; Figure 6D). JUND is a downstream 8 
substrate in ERK-MAPK signalling(32). Our previous analysis already suggested JUND 9 
activity be predictive of MEK-inhibition sensitivity alone. Here we show how JUND also 10 
improves response prediction to MEK inhibitor AZD6244 within HRAS mutant pancancer 11 
samples (p=1.21×10-7). Taken together, our results suggest that JUND regulon expression 12 
may be used as a sensor of ERK-MAPK pathway activity and vulnerability to MEK-inhibition. 13 
 14 
Finally, other potential interactions affecting well-established pharmacogenomic markers are: 15 
the interaction of JUND with cell cycle CDK4/CDK6 inhibitor in RB1 mutants (p=1.9×10-6), 16 
which modulate cyclins(42); sensitivity to AKT inhibitor GSK690693 interaction with several 17 
TFs in OV PIK3CA mutants, where the stronger hits involve EGR1 and CREB1 (p=5.1×10-6 18 
and p=7.6×10-3), downstream effectors of PI3K-Akt pathway(43); and, in HER2+ BRCA 19 
samples, sensitivity interaction between ELF1 activity and ERBB2 inhibitors Lapatinib and 20 
CP724714 (p=3.9×10-6 and p=8.9×10-5), a candidate regulator of ERBB2 expression(44).  21 
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Discussion 1 
TFs activities derived from gene expression data have attracted much attention in cancer 2 
research during the last years. Recent studies have used different strategies to derive TF 3 
activity profiles across different cancers, evaluated their potential as prognostic markers(8), 4 
and applied them to characterise the impact of cancer somatic alterations(6,7). Although 5 
based on different definitions of TF regulons, the common outcome is that estimating 6 
regulatory activities from the mRNA levels of the targeted genes can reveal known and novel 7 
mechanisms involved in tumor development. However, the potential of TF activities as 8 
markers to guide personalised treatments, alone or in combination with established genomic 9 
markers, has not yet been explored.  10 
Here, we applied a pipeline to derive signatures of TF activity from new and existing RNA-11 
seq data in 1,056 cancer cell lines and 9,250 primary tumors. Our approach combines 12 
consensus TF regulons (CTFRs) and gene-wise normalised expression data with 13 
unsupervised single-sample enrichment algorithms. This circumvents the need for a prior 14 
classification of samples into subtypes, of particular benefit when working with 15 
heterogeneous group of cancer samples, and does not require of unperturbed reference 16 
samples (often not available). Moreover, comparable TF activity signatures can be obtained 17 
for new samples by normalising the expression values of each gene against our reference 18 
panel of samples. 19 
TF activity profiles enabled us to (i) functionally characterise different TF mutations; (ii) link 20 
genomic aberrations in cancer driver genes with TF dysregulation; (iii) suggest new mechanisms 21 
for response to specific compounds in cancer models; and (iv) propose new markers of drug 22 
response, alone or in combination with genomic markers. Although we expect some 23 
interactions to reflect the cooperative behaviour between TFs controlling common processes 24 
rather than causal associations, these recapitulated known pharmacogenomic relationships 25 
and were enriched for TF-drug pairs close in the signalling network. Thus, we envision that 26 
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the identified associations provide reliable evidence to refine existing hypotheses or 1 
formulate new ones to understand therapeutic outcomes. Particularly, our study shows that 2 
predictions of therapeutic response can be improved if, in addition to the mutational status of 3 
a marker gene, the regulatory activity of the coded protein is also considered. This can be 4 
achieved directly when the marker gene codes for a TF (as exemplified by TP53-Nutlin3a 5 
response), or indirectly when the protein targeted by the drug regulates a TF (as the case of 6 
JUND in MEK inhibitors).  7 
The critical factor in the quantification of TF activities is the definition of the targets putatively 8 
regulated. Here, we chose to use a curated compendium of regulatory interactions 9 
(Consensus TF Regulons; CTFR) derived from different TF-DNA binding evidences such as 10 
in vivo ChIP-Seq experiments, in silico TFBS predictions and manual curations. The major 11 
limitations of our approach are: (i) CTFRs are restricted by prior knowledge, which may 12 
render incomplete regulons; (ii) the assumption that a TF either induces or represses its 13 
targets (but TFs may have both roles) and (iii) the cell-type dependencies of some TF-target 14 
interactions. Taken together, these limitations may cause inaccurate activity estimations for 15 
TFs with dual activator/repressor role or for TFs whose targets vary across cell types(45). 16 
Under these considerations, approaches inferring condition-specific regulons from 17 
transcriptomic associations have become popular(46). The underlying principle is that TF 18 
circuits can be inferred by correlating mRNA levels of the TFs with all other genes(47). 19 
However, our comparison revealed that activities derived from CTFRs perform slightly better 20 
than those from inferred regulons. Potential explanations may be that: (i) inference methods 21 
assume that mRNA levels are good activity indicators of the coded proteins, which may fail 22 
for TFs whose activity depends on post-translational regulation (such phosphorylation) or 23 
indeed their stoichiometric assembly as heteromeric complexes(48); (ii) these methods are 24 
susceptible of being confounded by indirect associations or co-expression with other 25 
TFs(49); (iii) regulons inferred from primary tumors may not capture regulatory events 26 
occurring in cell lines; and (iv) the pervasiveness of somatic mutations changing the function 27 
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of TFs. Pertinent examples are loss-of-function TP53 missense mutants which, while 1 
abundantly present at mRNA and protein level, are unable to regulate the expression of its 2 
canonical targets. Finally, the inference of such condition-specific networks requires a prior 3 
classification of samples, which may not be trivial for heterogeneous cancer cell line panels. 4 
An alternative could combine CTFRs with network inference approaches(50). 5 
Nonetheless, our TF predictions based on CTFRs agree with independent essentiality 6 
screenings and genomic data, and mimic changes in transactivation potential observed in 7 
mutagenesis studies. Importantly, CTFRs are able to reproduce known pharmacogenomic 8 
interactions while inferred regulons fail to do so. However, it is worth mentioning that our 9 
strategy to retrieve CTFRs may favour well-studied TFs, whose targets are thoroughly 10 
characterised, thus resulting in biased performances. Further refinement of the approaches 11 
to define TF regulons activity in cancer should enable to find further pharmacogenomic 12 
interactions, novel markers and therapeutic opportunities.  13 
Briefly, our results demonstrate that TF activity profiles derived from CTFRs can be used to 14 
characterise genomic alterations and drug response in cancer patients, proposing these as 15 
promising complementary therapeutic markers. The proposed approach may have strong 16 
implications in the refinement of personalised treatment methodologies. We envision that 17 
with the increase in the coverage and quality of the CTFRs, the proposed strategy will 18 
become instrumental to interpret transcriptional dysregulation in cancer and elucidate its 19 
clinical implications. 20 
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Figure legends 1 
Figure 1. Estimation of Transcription Factor (TF) activities overview. A) RNA-seq basal gene expression in 2 
cell lines data and TCGA samples (normal and tumors together) was processed separately to obtain normalised 3 
log-counts per million (CPM) that were then gene-wise normalised using a kernel estimation of the cumulative 4 
density function (kcdf). B) Consensus TFs regulons (CTFRs) were derived by selecting TF-target interactions 5 
observed in at least 2 sources among a collection of databases. In final CTFRs, targets under > 10 TFs and TFs 6 
with < 3 targets are removed. C) Estimation of single-sample TF activities from gene expression data and the 7 
CTFRs using the aREA algorithm from VIPER. Normal and tumor TCGA samples were analysed together. 8 
Figure 2. Transcription Factor (TF) activities across primary tumors and cancer cell lines. A) Heatmap of 9 
the differential TF activity (log fold change) between normal and tumoral samples across 14 tumor types. Red 10 
and blue indicate lower- and higher-activity in tumors, respectively, whereas white indicates non-significant (adj. 11 
p>0.05) associations. Only TFs with significant in at least 50% of the tumors are plotted. B) Tumor type similarity: 12 
Correlation based hierarchical clustering of tumor type-level TF activities for 23 primary tumors. C) Comparison of 13 
TF activities between primary tumors and cell lines for 19 common tumor types. Each value in the heatmap 14 
represents the pearson correlation coefficients between tumor type-level TF activities. Asterisks indicate 15 
significant correlations (adj. p<0.05). D) Activity distributions for tissue-specific TFs. Each point represents the TF 16 
activity in a given patient or cell line.  17 
 18 
Figure 3. Functional characterisation of mutant Transcription Factor (TF) on transcriptional activities. A) 19 
Functional evaluation of TF mutations on their own activity. B) Boxplot depicting TF activities according TP53 20 
mutation zygosity in cell lines. C) Comparison of the predicted effect size of significant TP53 mutations between 21 
primary tumors and cell lines. D) Systematic characterisation of mutant TFs in primary tumors. Each bar 22 
represents the number of significant mutant groups in the TF impacting its activity. Red and blue indicate positive 23 
and negative effects, respectively. E) Boxplots comparing TF activities across different variants for NFE2L2, 24 
AHR, FOXA1, REST and SREBF2. Red dots indicate that the mutation is reported in COSMIC v70.  25 
 26 
Figure 4. Functional characterisation of driver mutations on Transcription Factor (TF) activities. A) 27 
Volcano plot with effect size (x) and adjusted p-value (y) of all tested pancancer associations. B) Number of 28 
significant associations per TF in primary tumors and cell lines, coloured according to the sign of the association: 29 
red and blue correspond to significantly higher or lower TF activities in mutants compared to wild-type, 30 
respectively. C) Significant (FDR<5%) the TF-driver associations from primary tumors and cell lines and the 31 
overlap. Shared driver-TF pairs are indicated in the table. D) Log odds-ratio of finding a significant interaction by 32 
network distance (minimum number of directed intermediates between the driver and the corresponding TF). ** 33 
indicates p<0.05; ***p<0.001 (FET). E) Enrichment in positive/negative driver-TF associations (red/blue, 34 
respectively) to involve oncogenic/tumor-suppressor TFs, respectively. 35 
  36 
Figure 5. Associations between Transcription Factor (TF) activities and drug sensitivity. A) Frequency of 37 
TFs in significant pancancer TF-drug associations. B) Enrichment p-values for drug classes that are 38 
overrepresented among significant pancancer associations. C and D) Heatmaps of significant associations with 39 
with drugs targeting ERK-MAPK pathway (C) and cytotoxic drugs (D). E) Volcano plot with effect size (x) and 40 
adjusted p-value (y) of all tested pancancer TF-drug associations. Red and blue indicate positive (resistance) and 41 
negative (sensitivity) effects, respectively. F) Volcano plot with effect size (x) and adjusted p-value (y) of all tested 42 
cancer-specific TF-drug associations. G) Examples of cancer-specific TF-drug associations. Red and blue 43 
indicate positive (resistance) and negative (sensitivity) effects, respectively. 44 
 45 
Figure 6. Modelling the combined effect on drug sensitivity of known pharmacogenomic markers and 46 
Transcription Factor (TF) activities. A) Analysis strategy: 2 pharmacogenomic regression models are built, one 47 
without any TF information (null model) and another including the activity of a TF (test model). Both models are 48 
compared using a Likelihood Ratio test. B) Improvement of the association TP53MUTNutlin-3a by including TP53 49 
TF activity. C) Improvement of the association BRAFMUT-Dabrafenib by including ATF2 TF activity. D) 50 
Improvement of the association BRAFMUT-Trametinib by including JUND TF activity. Left box represents the top 51 
TFs improving the null pharmacogenomic model. Indicated p-values are nominal, with FDR<0.05. First boxplot 52 
represents the IC50 (y) in mutant (blue) and WT (red) samples (x). The second scatterplot represents the IC50 53 
(y) and the predicted TF activity (x). The third scatterplot represents the interaction between the IC50 (y) and the 54 
predicted TF activity (x) in mutant (blue) and WT (red) samples. The fourth boxplot represents the IC50 (y) in 55 
Research. 
on December 18, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 11, 2017; DOI: 10.1158/0008-5472.CAN-17-1679 
28 
mutant and WT samples (x) coloured according to the TF activity (low: activity<-1; basal: -1<activity<1; high: 1 
activity>1). 2 
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